Frenvas 20 mg (Tablet)
Medicine Details
Category | Details |
---|---|
Generic | Atorvastatin calcium |
Company | Radiant pharmaceuticals ltd |
Also available as |
Indications
- Reduce elevated total cholesterol levels
- Reduce LDL cholesterol levels
- Reduce apolipoprotein B levels
- Reduce triglycerides levels
- Treat heterozygous and homozygous familial hypercholesterolaemia
- Treat mixed dyslipidemia
- Treat hypertriglyceridaemia
- Treat dysbetalipoproteinaemia
- Reduce cardiac ischaemic events
- Treat hypercholesterolemia associated with diabetes mellitus or renal transplantation
Pharmacology
- Selective inhibitor of HMG-CoA reductase
- Lowers plasma cholesterol and lipoprotein levels
- Inhibits cholesterol synthesis in the liver
- Increases hepatic LDL receptors for enhanced uptake of LDL
- Rapidly absorbed after oral administration
- Extensively metabolized to active metabolites
- Eliminated primarily in bile
- Has a plasma elimination half-life of approximately 14 hours
Dosage & Administration
- Adult dosage: 10 mg to 80 mg once daily
- Pediatric dosage: 10 mg to 20 mg once daily
- Initial dosage may be increased at intervals of at least 4 weeks
- Recommended starting dose of 10 mg to 20 mg once daily
- Analysis of lipid levels within 2 to 4 weeks after initiation of treatment
Interaction
- Increased risk of myopathy with concurrent use of certain drugs
- Plasma concentration changes when coadministered with antacids, colestipol, digoxin, erythromycin, oral contraceptives, warfarin
Contraindications
- Hypersensitivity to any component of the medication
- Active liver disease
- Unexplained persistent elevations of serum transaminases
- History of serious adverse reaction to prior administration of HMG-CoA reductase inhibitors
Side Effects
- Constipation
- Flatulence
- Dyspepsia
- Abdominal pain
- Infection
- Headache
- Back pain
- Rash
- Asthenia
- Arthralgia
- Myalgia
Pregnancy & Lactation
- Atorvastatin contraindicated during pregnancy
- No established safety in pregnant women
- Animal studies show toxicity to reproduction
- Not known if excreted in human milk
- Should not be used during breastfeeding
Precautions & Warnings
- Liver function tests should be performed before initiation of treatment
- Discontinue therapy if markedly elevated CPK levels occur or myopathy is diagnosed or suspected
- Use with caution in patients with substantial alcohol consumption or history of liver disease
Use in Special Populations
- Higher plasma concentrations in elderly subjects
- No clinically significant difference in LDL-C reduction between men and women
- No dose adjustment necessary in renal dysfunction
- No significant clearance enhancement with hemodialysis
- Markedly increased plasma concentrations in patients with chronic alcoholic liver disease
Overdose Effects
- No specific treatment available
- Symptomatic and supportive measures should be instituted
- Liver function tests and serum CK levels should be monitored
Therapeutic Class
- Other Anti-anginal & Anti-ischaemic drugs
- Statins
Storage Conditions
- Keep in a dry place away from light and heat
- Keep out of the reach of children
Chemical Structure
- Molecular Formula: C33H35FN2O5
Common Questions about Frenvas 20 mg Tablet
- Used to avoid heart attacks and Primary Hypercholesterolemia
- Taken by mouth once daily, with or without food
- Used for the treatment of Mixed Dyslipidemia and Hypertriglyceridemia
- Possible side-effects include cough, muscle pain, breathing difficulty, and running nose
- Should be stored at room temperature, away from heat and direct light
- Classified as a statin and helps in decreasing the level of lipids or fats in the blood
- Can slightly affect blood sugar levels in type 2 diabetes patients
- Should be taken for the duration prescribed by a doctor and considered safe for long term use if taken as directed
- Does not cause weight loss or thinning of the blood
- Not recommended for use in children under 10 years old
- Quick tips for safe usage
Antacid Interaction
When atorvastatin and antacid suspension were coadministered, plasma concentrations of atorvastatin decreased approximately 35%
Colestipol Interaction
Plasma concentrations of atorvastatin decreased approximately 25% when colestipol and atorvastatin were coadministered
Digoxin Interaction
When multiple doses of atorvastatin and digoxin were coadministered, steady-state plasma digoxin concentrations increased by approximately 20%
Erythromycin Interaction
In healthy individuals, plasma concentrations of atorvastatin increased approximately 40% with coadministration of atorvastatin and erythromycin, a known inhibitor of cytochrome P450 3A4
Oral Contraceptives Interaction
Coadministration of atorvastatin and an oral contraceptive increased AUC values for norethindrone and ethinyl estradiol by approximately 30% and 20%
Warfarin Interaction
Frenvas had no clinically significant effect on prothrombin time when administered to patients receiving chronic warfarin treatment